



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: contact@samratpharmachem.in

November 14, 2019

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 14, 2019, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2019, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Sandeep Prajapati
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Standalone Unaudited Results for the Quarter Ended 30 September, 2019

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Sep-19 (Unaudited)	Quarter Ended 30-Jun-19 (Unaudited)	Quarter Ended 30-Sep-18 (Unaudited)	Year to date ended 30-Sep-19 (Unaudited)	Year to date ended 30-Sep-18 (Unaudited)	Year Ended 31-Mar-19 (Audited)
1 (a). Revenue from Operations	3,653.82	3,548.05	2,263.19	7,201.88	4,733.49	11,113.64
(b). Other Income	41.87	4.08	2.95	45.94	23.92	45.67
Total Revenue	3,695.69	3,552.13	2,266.14	7,247.82	4,757.41	11,159.31
2. Expenditure						
a) Cost of materials consumed	3,300.90	3,212.54	2,342.28	6,513.44	4,694.52	10,353.24
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	29.85	(72.89)	(225.71)	(43.04)	(245.61)	(90.93)
d) Employee Costs	30.25	29.07	28.27	59.32	55.37	138.36
e) Interest	22.73	16.66	20.79	39.39	45.12	105.84
f) Depreciation & Amortisation expense	10.66	10.53	10.49	21.19	20.74	41.77
g) Other Expenses	86.24	101.43	95.37	187.67	178.67	395.27
Total	3,480.63	3,297.34	2,271.49	6,777.97	4,748.81	10,943.55
3. Profit before exceptional & extraordinary items & tax	215.06	254.79	(5.35)	469.85	8.60	215.76
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5. Profit before extraordinary items & tax	215.06	254.79	(5.35)	469.85	8.60	215.76
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	215.06	254.79	(5.35)	469.85	8.60	215.76
8. Tax expense						
a) Current Tax	(52.51)	(63.79)	3.34	(116.30)	(0.26)	(61.46)
b) Deferred Tax	(12.29)	(3.99)	(7.03)	(16.28)	(13.20)	(0.75)
Total Tax Expense	(64.80)	(67.78)	(3.69)	(132.58)	(13.46)	(62.21)
9. Profit (Loss) for the period after tax	150.26	187.01	(9.04)	337.27	(4.86)	153.55
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	150.26	187.01	(9.04)	337.27	(4.86)	153.55
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	4.86	6.05	(0.29)	10.92	(0.16)	4.97
b) Diluted	4.86	6.05	(0.29)	10.92	(0.16)	4.97



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Assets & Liabilities

PARTICULARS	(Rs. in lakhs) (Rs. in lakhs)	
	Standalone	Standalone
	AS ON 30-Sep-19 Un-Audited	AS ON 31-Mar-19 Audited
ASSETS		
Non Current Assets		
Property, Plant and Equipment	695.84	685.28
Capital Work-in-progress	61.92	0
Intangible Assets	0.39	1.02
Intangible Assets under development	-	0
Financial Assets		
Investments	-	-
Loans	20.92	9.68
Deferred Tax Assets (Net)	-	-
Other Non-Current Assets	46.07	50.82
Total Non Current Assets	825.14	746.80
CURRENT ASSETS		
Inventories	899.12	792.96
Financial Assets		
Investments	0.10	0.10
Trade Receivables	2,964.96	2,104.79
Cash And Cash Equivalents	327.95	224.62
Loans	-	2.46
Other Financial Assets	-	-
Other Current Assets	28.93	150.93
Total Current Assets	4,221.06	3,275.86
Total- Assets	5,046.20	4,022.66
<u>EQUITY AND LIABILITIES</u>		
Equity		
Equity Share Capital	308.97	308.97
Other Equity	2,035.00	1,697.72
Total Equity	2,343.97	2,006.69
Non-Current Liabilities		
Financial Liabilities		
Borrowings	7.30	31.28
Provisions	-	-
Deferred Tax Liabilities (Net)	48.45	32.17
Other Long Current Liabilities	-	19.63
Total Non-Current Liabilities	55.75	83.08
Current Liabilities		
Financial Liabilities		
Borrowings	1,057.19	577.16
Trade Payables	1,405.44	1,265.63
Other Financial Liabilities	-	-
Other Current Liabilities	68.33	53.40
Provisions	115.52	36.70
Total Current Liabilities	2,646.48	1,932.89
Total Liabilities	5,046.20	4,022.66



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 September, 2019.
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Thursday, 14 November 2019 at the Corporate Office of the Company.
4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 30 September 2019 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
5. The Company manufactures pharmaceutical chemicals, which is a single business segment.
6. Figures for the previous period have been regrouped / reclassified, wherever necessary.

**By order of the Board of Directors
For Samrat Pharmachem Limited**

**Rajesh Mehta
Executive Director
DIN: 00216731**



Place : Mumbai

Date : 14 November 2019



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance

CA Nihar Dharod
Indirect Tax & Litigation

Independent Auditor's Report on Limited Review of the Unaudited Quarterly/ Half Yearly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

**To Board of Directors
Samrat Pharmachem Limited**

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30th September, 2019 and year to date from 1st April, 2019 to 30th September, 2019 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financials statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder other accounting policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For SHAH & SAVLA LLP
Chartered Accountants
Firm Reg: No.:109364W/W100143**

**CA. Miral H. Nagda
(Partner)**

Membership No. 108135

UDIN: 19108135 AAAAEG-2716

Place: Mumbai

Date: **14 NOV 2019**

